INTRODUCTION
We present a case of 68 year old female who developed symptomatic hypocalcaemia post-thyroidectomy, which she had for multinodular goitre. Previously she had ileostomy for severe faecal incontinence. Other medical problems include active colitis of indeterminate histology, duodenal ulcer and diverticular disease.
Despite treatment with suprapharmacological doses of oral calcium supplements, she remained severely hypocalcaemic, and often presented to hospital with tetany.
Transient hypocalcaemia is common following thyroidectomy. However severe refractory hypocalcaemia is rare. We present this case which was challenging to manage with conventional therapies. She successfully responded to a continuous infusion of teriparatide. Table 1 shows comparison of levels pre-and post-operatively. Other causes of hypocalcaemia were excluded and concomitant Vitamin D deficiency was treated. Step Number
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DISCUSSION
We faced few challenges in managing this patient with refractory hypocalcaemia post-thyroidectomy. She had multiple hospital admissions with symptomatic hypocalcaemia requiring intravenous replacement. To-date she had 10 admissions, often followed by prolonged hospital stay. In addition, she also required regular attendances to the Medical Day Unit for blood monitoring as well as intravenous treatment for less severe presentations.
As part of the intended long term therapy, she was initially commenced on oral calcium, magnesium and vitamin D tablets. However despite increasing the doses, the serum levels remained low.
We observed 3 limitations with oral therapies:
• Intolerance to calcium and magnesium salts, which were associated with worsening of gastrointestinal symptoms (nausea and high stoma output)
• Intermittent flare-up of colitis, which coincided with hypocalcaemia
• Failure to obtain optimal levels of calcium and magnesium despite suprapharmacological doses
Following literature reviews on Teriparatide treatment for hypocalcaemia (1,2), we introduced subcutaneous Teriparatide injections in addition to the oral therapies. The initial dose was 20mcg BD, which was later increased to 40mcg BD. However despite this, serum calcium level remained suboptimal requiring multiple admissions for intravenous replacement. We suspected this could be due an underlying physiological mechanism as explained by J.Satterwhite et al (3) . From their observation, Teriparatide injections transiently increased serum calcium levels but these returned to pre-dose levels 16 hours after each dose. Persistent hypercalcemia was not observed. Following once-daily subcutaneous administration, Teriparatide produces a modest but transient increase in serum calcium, consistent with the known effects of endogenous PTH on mineral metabolism.
In view of failure of treatment, we switched the Teriparatide injections to subcutaneous continuous infusion at a dose of 40 mcg over 24 hours. It was later increased to 60 mcg over 24 hours and therapeutic sustained calcium levels were achieved. This led to significant reduction in the number of her hospital admissions.
TERIPARATIDE: MODE OF ACTION

CONCLUSION
Continuous subcutaneous infusion of Teriparatide has been shown to be safe and effective in the management of this patient who has refractory hypocalcaemia post-thyroidectomy. We will continue to observe its effectiveness, development of side effects as well as resistance.
SYRINGE DRIVER DEVICE USED FOR DELIVERY OF TERIPARATIDE INFUSION
